APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oncology Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025194 pages

Choose your research edition.

Industry ResearchOncology Biosimilars Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Biosimilars Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Oncology Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Biosimilars Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Biosimilars Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Oncology Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oncology Biosimilars include Teva Pharmaceutical Industries Ltd, Sandoz International, Pfizer, STADA Arzneimittel AG, Intas Pharmaceuticals, Dr. Reddy’s Laboratories, Celltrion, Biocon and BIOCAD, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Oncology Biosimilars market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology Biosimilars and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Biosimilars revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Oncology Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Oncology Biosimilars Segment by Company

Teva Pharmaceutical Industries Ltd

Sandoz International

Pfizer

STADA Arzneimittel AG

Intas Pharmaceuticals

Dr. Reddy’s Laboratories

Celltrion

Biocon

BIOCAD

Apotex

Oncology Biosimilars Segment by Type

Hematopoietic Agents

Monoclonal Antibody

G-CSF

Others

Oncology Biosimilars Segment by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacies

Oncology Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Oncology Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Biosimilars industry.

Chapter 3: Detailed analysis of Oncology Biosimilars companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Biosimilarsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncology Biosimilars Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Hematopoietic Agents Table 3. Key Players of Monoclonal Antibody Table 4. Key Players of G-CSF Table 3. Key Players of Others Table 4. Global Oncology Biosimilars Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Pharmacy Table 6. Key Players of Online Pharmacy Table 7. Key Players of Retail Pharmacies Table 8. Global Oncology Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Oncology Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Oncology Biosimilars Market Share by Region (2021-2026) Table 11. Global Oncology Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Oncology Biosimilars Market Share by Region (2027-2032) Table 13. Oncology Biosimilars Industry Trends Table 14. Oncology Biosimilars Industry Drivers Table 15. Oncology Biosimilars Industry Opportunities and Challenges Table 16. Oncology Biosimilars Industry Restraints Table 17. Global Oncology Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Oncology Biosimilars Revenue Market Share by Company (2021-2026) Table 19. Global Oncology Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Oncology Biosimilars Key Company Head Office and Area Served Table 21. Global Oncology Biosimilars Company, Product Type & Application Table 22. Global Oncology Biosimilars Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Oncology Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Oncology Biosimilars Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Oncology Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Oncology Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Oncology Biosimilars Revenue Market Share by Type (2021-2026) Table 29. Global Oncology Biosimilars Revenue Market Share by Type (2027-2032) Table 30. Global Oncology Biosimilars Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oncology Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Oncology Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Oncology Biosimilars Revenue Market Share by Application (2021-2026) Table 34. Global Oncology Biosimilars Revenue Market Share by Application (2027-2032) Table 35. Teva Pharmaceutical Industries Ltd Company Information Table 36. Teva Pharmaceutical Industries Ltd Business Overview Table 37. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio Table 39. Teva Pharmaceutical Industries Ltd Recent Development Table 40. Sandoz International Company Information Table 41. Sandoz International Business Overview Table 42. Sandoz International Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sandoz International Oncology Biosimilars Product Portfolio Table 44. Sandoz International Recent Development Table 45. Pfizer Company Information Table 46. Pfizer Business Overview Table 47. Pfizer Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Pfizer Oncology Biosimilars Product Portfolio Table 49. Pfizer Recent Development Table 50. STADA Arzneimittel AG Company Information Table 51. STADA Arzneimittel AG Business Overview Table 52. STADA Arzneimittel AG Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. STADA Arzneimittel AG Oncology Biosimilars Product Portfolio Table 54. STADA Arzneimittel AG Recent Development Table 55. Intas Pharmaceuticals Company Information Table 56. Intas Pharmaceuticals Business Overview Table 57. Intas Pharmaceuticals Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Intas Pharmaceuticals Oncology Biosimilars Product Portfolio Table 59. Intas Pharmaceuticals Recent Development Table 60. Dr. Reddy’s Laboratories Company Information Table 61. Dr. Reddy’s Laboratories Business Overview Table 62. Dr. Reddy’s Laboratories Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio Table 64. Dr. Reddy’s Laboratories Recent Development Table 65. Celltrion Company Information Table 66. Celltrion Business Overview Table 67. Celltrion Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Celltrion Oncology Biosimilars Product Portfolio Table 69. Celltrion Recent Development Table 70. Biocon Company Information Table 71. Biocon Business Overview Table 72. Biocon Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Biocon Oncology Biosimilars Product Portfolio Table 74. Biocon Recent Development Table 75. BIOCAD Company Information Table 76. BIOCAD Business Overview Table 77. BIOCAD Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. BIOCAD Oncology Biosimilars Product Portfolio Table 79. BIOCAD Recent Development Table 80. Apotex Company Information Table 81. Apotex Business Overview Table 82. Apotex Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Apotex Oncology Biosimilars Product Portfolio Table 84. Apotex Recent Development Table 85. North America Oncology Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 86. North America Oncology Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 87. North America Oncology Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 88. North America Oncology Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 89. North America Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Oncology Biosimilars Market Size by Country (2021-2026) Table 91. North America Oncology Biosimilars Market Size by Country (2027-2032) Table 92. Europe Oncology Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 93. Europe Oncology Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 94. Europe Oncology Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 95. Europe Oncology Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 96. Europe Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Oncology Biosimilars Market Size by Country (2021-2026) Table 98. Europe Oncology Biosimilars Market Size by Country (2027-2032) Table 99. China Oncology Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 100. China Oncology Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 101. China Oncology Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 102. China Oncology Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 103. Asia Oncology Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 104. Asia Oncology Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 105. Asia Oncology Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 106. Asia Oncology Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 107. Asia Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Oncology Biosimilars Market Size by Country (2021-2026) Table 109. Asia Oncology Biosimilars Market Size by Country (2027-2032) Table 110. South America, Middle East & Africa Oncology Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 111. South America, Middle East & Africa Oncology Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 112. South America, Middle East & Africa Oncology Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 113. South America, Middle East & Africa Oncology Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 114. South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2021-2026) Table 116. South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Oncology Biosimilars Product Image Figure 2. Global Oncology Biosimilars Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Oncology Biosimilars Market Share by Type: 2025 VS 2032 Figure 4. Hematopoietic Agents Image Figure 5. Monoclonal Antibody Image Figure 6. G-CSF Image Figure 7. Others Image Figure 8. Global Oncology Biosimilars Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Oncology Biosimilars Market Share by Application: 2025 VS 2032 Figure 10. Hospital Pharmacy Image Figure 11. Online Pharmacy Image Figure 12. Retail Pharmacies Image Figure 13. Global Oncology Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 15. Global Oncology Biosimilars Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Oncology Biosimilars Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Oncology Biosimilars Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Oncology Biosimilars Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Oncology Biosimilars Revenue Market Share by Type (2021-2032) Figure 22. Global Oncology Biosimilars Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Oncology Biosimilars Revenue Market Share by Application (2021-2032) Figure 24. North America Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 25. North America Oncology Biosimilars Market Share by Type (2021-2032) Figure 26. North America Oncology Biosimilars Market Share by Application (2021-2032) Figure 27. North America Oncology Biosimilars Market Share by Country (2021-2032) Figure 28. United States Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 29. Canada Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 31. Europe Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 32. Europe Oncology Biosimilars Market Share by Type (2021-2032) Figure 33. Europe Oncology Biosimilars Market Share by Application (2021-2032) Figure 34. Europe Oncology Biosimilars Market Share by Country (2021-2032) Figure 35. Germany Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 36. France Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 38. Italy Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 39. Russia Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 41. China Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 42. China Oncology Biosimilars Market Share by Type (2021-2032) Figure 43. China Oncology Biosimilars Market Share by Application (2021-2032) Figure 44. Asia Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 45. Asia Oncology Biosimilars Market Share by Type (2021-2032) Figure 46. Asia Oncology Biosimilars Market Share by Application (2021-2032) Figure 47. Asia Oncology Biosimilars Market Share by Country (2021-2032) Figure 48. Japan Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 52. India Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 53. Australia Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Oncology Biosimilars Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Oncology Biosimilars Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Oncology Biosimilars Market Share by Country (2021-2032) Figure 58. Brazil Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 63. UAE Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 65. Chile Oncology Biosimilars Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Hematopoietic Agents
  • Monoclonal Antibody
  • G-CSF
  • Others
Applications
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacies
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International
  • Pfizer
  • STADA Arzneimittel AG
  • Intas Pharmaceuticals
  • Dr. Reddy’s Laboratories
  • Celltrion
  • Biocon
  • BIOCAD
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Oncology Biosimilars Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Hematopoietic Agents
  5. 1.2.3 Monoclonal Antibody
  6. 1.2.4 G-CSF
  7. 1.2.5 Others
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Oncology Biosimilars Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacy
  11. 1.3.3 Online Pharmacy
  12. 1.3.4 Retail Pharmacies
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Oncology Biosimilars Growth Trends by Region
  15. 1.5.1 Global Oncology Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Oncology Biosimilars Market Size by Region (2021-2026)
  17. 1.5.3 Oncology Biosimilars Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Oncology Biosimilars Market Dynamics
  1. 2.1 Oncology Biosimilars Industry Trends
  2. 2.2 Oncology Biosimilars Industry Drivers
  3. 2.3 Oncology Biosimilars Industry Opportunities and Challenges
  4. 2.4 Oncology Biosimilars Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Oncology Biosimilars Revenue by Company (2021-2026)
  2. 3.2 Global Oncology Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Oncology Biosimilars Key Company Head office and Area Served
  4. 3.4 Global Oncology Biosimilars Company, Product Type & Application
  5. 3.5 Global Oncology Biosimilars Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Oncology Biosimilars Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Oncology Biosimilars Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Oncology Biosimilars Tier 1, Tier 2, and Tier 3
4 Oncology Biosimilars Market by Type
  1. 4.1 Global Oncology Biosimilars Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Oncology Biosimilars Market Size by Type (2021-2032)
  3. 4.3 Global Oncology Biosimilars Market Size Share by Type (2021-2032)
5 Oncology Biosimilars Market by Application
  1. 5.1 Global Oncology Biosimilars Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Oncology Biosimilars Market Size by Application (2021-2032)
  3. 5.3 Global Oncology Biosimilars Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries Ltd
  2. 6.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 6.2 Sandoz International
  8. 6.2.1 Sandoz International Company Information
  9. 6.2.2 Sandoz International Business Overview
  10. 6.2.3 Sandoz International Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Sandoz International Oncology Biosimilars Product Portfolio
  12. 6.2.5 Sandoz International Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pfizer Oncology Biosimilars Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 STADA Arzneimittel AG
  20. 6.4.1 STADA Arzneimittel AG Company Information
  21. 6.4.2 STADA Arzneimittel AG Business Overview
  22. 6.4.3 STADA Arzneimittel AG Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 STADA Arzneimittel AG Oncology Biosimilars Product Portfolio
  24. 6.4.5 STADA Arzneimittel AG Recent Developments
  25. 6.5 Intas Pharmaceuticals
  26. 6.5.1 Intas Pharmaceuticals Company Information
  27. 6.5.2 Intas Pharmaceuticals Business Overview
  28. 6.5.3 Intas Pharmaceuticals Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Intas Pharmaceuticals Oncology Biosimilars Product Portfolio
  30. 6.5.5 Intas Pharmaceuticals Recent Developments
  31. 6.6 Dr. Reddy’s Laboratories
  32. 6.6.1 Dr. Reddy’s Laboratories Company Information
  33. 6.6.2 Dr. Reddy’s Laboratories Business Overview
  34. 6.6.3 Dr. Reddy’s Laboratories Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio
  36. 6.6.5 Dr. Reddy’s Laboratories Recent Developments
  37. 6.7 Celltrion
  38. 6.7.1 Celltrion Company Information
  39. 6.7.2 Celltrion Business Overview
  40. 6.7.3 Celltrion Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Celltrion Oncology Biosimilars Product Portfolio
  42. 6.7.5 Celltrion Recent Developments
  43. 6.8 Biocon
  44. 6.8.1 Biocon Company Information
  45. 6.8.2 Biocon Business Overview
  46. 6.8.3 Biocon Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Biocon Oncology Biosimilars Product Portfolio
  48. 6.8.5 Biocon Recent Developments
  49. 6.9 BIOCAD
  50. 6.9.1 BIOCAD Company Information
  51. 6.9.2 BIOCAD Business Overview
  52. 6.9.3 BIOCAD Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 BIOCAD Oncology Biosimilars Product Portfolio
  54. 6.9.5 BIOCAD Recent Developments
  55. 6.10 Apotex
  56. 6.10.1 Apotex Company Information
  57. 6.10.2 Apotex Business Overview
  58. 6.10.3 Apotex Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Apotex Oncology Biosimilars Product Portfolio
  60. 6.10.5 Apotex Recent Developments
7 North America
  1. 7.1 North America Oncology Biosimilars Market Size (2021-2032)
  2. 7.2 North America Oncology Biosimilars Market Size by Type
  3. 7.2.1 North America Oncology Biosimilars Market Size by Type (2021-2026)
  4. 7.2.2 North America Oncology Biosimilars Market Size by Type (2027-2032)
  5. 7.2.3 North America Oncology Biosimilars Market Share by Type (2021-2032)
  6. 7.3 North America Oncology Biosimilars Market Size by Application
  7. 7.3.1 North America Oncology Biosimilars Market Size by Application (2021-2026)
  8. 7.3.2 North America Oncology Biosimilars Market Size by Application (2027-2032)
  9. 7.3.3 North America Oncology Biosimilars Market Share by Application (2021-2032)
  10. 7.4 North America Oncology Biosimilars Market Size by Country
  11. 7.4.1 North America Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Oncology Biosimilars Market Size by Country (2021-2026)
  13. 7.4.3 North America Oncology Biosimilars Market Size by Country (2027-2032)
  14. 7.4.4 North America Oncology Biosimilars Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Oncology Biosimilars Market Size (2021-2032)
  2. 8.2 Europe Oncology Biosimilars Market Size by Type
  3. 8.2.1 Europe Oncology Biosimilars Market Size by Type (2021-2026)
  4. 8.2.2 Europe Oncology Biosimilars Market Size by Type (2027-2032)
  5. 8.2.3 Europe Oncology Biosimilars Market Share by Type (2021-2032)
  6. 8.3 Europe Oncology Biosimilars Market Size by Application
  7. 8.3.1 Europe Oncology Biosimilars Market Size by Application (2021-2026)
  8. 8.3.2 Europe Oncology Biosimilars Market Size by Application (2027-2032)
  9. 8.3.3 Europe Oncology Biosimilars Market Share by Application (2021-2032)
  10. 8.4 Europe Oncology Biosimilars Market Size by Country
  11. 8.4.1 Europe Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Oncology Biosimilars Market Size by Country (2021-2026)
  13. 8.4.3 Europe Oncology Biosimilars Market Size by Country (2027-2032)
  14. 8.4.4 Europe Oncology Biosimilars Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Oncology Biosimilars Market Size (2021-2032)
  2. 9.2 China Oncology Biosimilars Market Size by Type
  3. 9.2.1 China Oncology Biosimilars Market Size by Type (2021-2026)
  4. 9.2.2 China Oncology Biosimilars Market Size by Type (2027-2032)
  5. 9.2.3 China Oncology Biosimilars Market Share by Type (2021-2032)
  6. 9.3 China Oncology Biosimilars Market Size by Application
  7. 9.3.1 China Oncology Biosimilars Market Size by Application (2021-2026)
  8. 9.3.2 China Oncology Biosimilars Market Size by Application (2027-2032)
  9. 9.3.3 China Oncology Biosimilars Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Oncology Biosimilars Market Size (2021-2032)
  2. 10.2 Asia Oncology Biosimilars Market Size by Type
  3. 10.2.1 Asia Oncology Biosimilars Market Size by Type (2021-2026)
  4. 10.2.2 Asia Oncology Biosimilars Market Size by Type (2027-2032)
  5. 10.2.3 Asia Oncology Biosimilars Market Share by Type (2021-2032)
  6. 10.3 Asia Oncology Biosimilars Market Size by Application
  7. 10.3.1 Asia Oncology Biosimilars Market Size by Application (2021-2026)
  8. 10.3.2 Asia Oncology Biosimilars Market Size by Application (2027-2032)
  9. 10.3.3 Asia Oncology Biosimilars Market Share by Application (2021-2032)
  10. 10.4 Asia Oncology Biosimilars Market Size by Country
  11. 10.4.1 Asia Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Oncology Biosimilars Market Size by Country (2021-2026)
  13. 10.4.3 Asia Oncology Biosimilars Market Size by Country (2027-2032)
  14. 10.4.4 Asia Oncology Biosimilars Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Oncology Biosimilars Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Oncology Biosimilars Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Oncology Biosimilars Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Oncology Biosimilars Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Oncology Biosimilars Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Oncology Biosimilars Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Oncology Biosimilars Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Oncology Biosimilars Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Oncology Biosimilars Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Oncology Biosimilars Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Oncology Biosimilars Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst